- The new directors at KaloBios Pharmaceuticals (KBIO) have decided to withdraw the company's Nasdaq appeal, opting instead to focus the firm's resources on executing its business plan and reorganization. Accordingly, the stock will be delisted today. Shares will be eligible to trade in over-the-counter markets.
- Previously: Nasdaq clarifies bases for KaloBios delisting (Dec. 31, 2015)
- Previously: KaloBios files delisting appeal, hearing set for February 25 (Dec. 29, 2015)
-
Update: Shares are changing hands over-the-counter at ~$2, down 92% from $25, the price level when halted by Nasdaq on December 17.